BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)

Phase 2

Completed

Conditions: Anemia
Renal Insufficiency, Chronic

Interventions: Drug: BAY85-3934
Drug: Placebo

First Posted Date: 2013-12-27

Last Posted Date: 2019-09-20

Lead Sponsor: Bayer

Target Recruit Count: 121

Registration Number: NCT02021370

Locations: 🇹🇷
Sifa University Medical Faculty, Izmir, Turkey
🇹🇷
Ankara Univ. Medical Faculty, Ankara, Turkey
🇹🇷
Baskent University Medical Faculty, Ankara, Turkey

Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934

Phase 2

Completed

Conditions: Renal Insufficiency, Chronic
Anemia

Interventions: Drug: BAY85-3934
Biological: Darbepoetin alfa

First Posted Date: 2013-12-27

Last Posted Date: 2019-09-19

Lead Sponsor: Bayer

Target Recruit Count: 126

Registration Number: NCT02021409

Locations: 🇹🇷
Baskent University Medical Faculty, Ankara, Turkey
🇹🇷
Ankara Univ. Medical Faculty, Ankara, Turkey
🇹🇷
Sifa University Medical Faculty, Izmir, Turkey

Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor

Phase 3

Completed

Conditions: Hypertension, Pulmonary

Interventions: Drug: Riociguat (Adempas, BAY63-2521)

First Posted Date: 2013-12-11

Last Posted Date: 2019-02-21

Lead Sponsor: Bayer

Target Recruit Count: 61

Registration Number: NCT02007629

Effect of Neomycin on the Pharmacokinetics of Regorafenib

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)
Drug: Neomycin

First Posted Date: 2013-12-05

Last Posted Date: 2015-08-13

Lead Sponsor: Bayer

Target Recruit Count: 27

Registration Number: NCT02001909

Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: Sorafenib (Nexavar, BAY 43-9006)

First Posted Date: 2013-11-13

Last Posted Date: 2018-02-07

Lead Sponsor: Bayer

Target Recruit Count: 61

Registration Number: NCT01982097

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Rogaratinib (BAY1163877) oral solution
Drug: Rogaratinib (BAY1163877) 800 mg BID
Drug: Rogaratinib (BAY1163877) oral tablet

First Posted Date: 2013-11-06

Last Posted Date: 2021-05-06

Lead Sponsor: Bayer

Target Recruit Count: 168

Registration Number: NCT01976741

Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934

Phase 2

Completed

Conditions: Renal Insufficiency, Chronic
Anemia

Interventions: Drug: Molidustat (BAY 85-3934)
Biological: Epoetin alfa/beta

First Posted Date: 2013-11-05

Last Posted Date: 2019-09-20

Lead Sponsor: Bayer

Target Recruit Count: 201

Registration Number: NCT01975818

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Regorafenib (Stivarga, BAY73-4506)
Drug: Cetuximab (ERBITUX)

First Posted Date: 2013-11-01

Last Posted Date: 2019-04-09

Lead Sponsor: Bayer

Target Recruit Count: 42

Registration Number: NCT01973868

Locations: 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Medical Center Health System, Pittsburgh, Pennsylvania, United States

and more 1 locations

Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension

Completed

Conditions: Hypertension, Pulmonary

Interventions: Drug: Iloprost (Ventavis, BAYQ6256)

First Posted Date: 2013-10-29

Last Posted Date: 2019-03-26

Lead Sponsor: Bayer

Target Recruit Count: 89

Registration Number: NCT01971450

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)

Phase 2

Completed

Conditions: Diabetic Nephropathies

Interventions: Drug: BAY94-8862
Drug: Placebo
Drug: BAY 94-8862

First Posted Date: 2013-10-24

Last Posted Date: 2021-07-16

Lead Sponsor: Bayer

Target Recruit Count: 96

Registration Number: NCT01968668

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy